icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Summit Therapeutics (SMMT.US) beats "King of Drugs" with double-antibody drug data, gets Citigroup's preferred stock and raises target price

Market VisionMonday, Sep 9, 2024 8:40 pm ET
1min read

Zhitong Finance learned that Summit Therapeutics' (SMMT.US) double-antibody drug Ivonescimab (PD-1/VEGF double-antibody) reduced the risk of disease progression or death by 49% compared with Merck's (MRK.US) key cancer drug Keytruda in the treatment of non-small cell lung cancer (NSCLC), according to clinical data previously released. After the data was released, Citigroup praised the data in a new report and recommended Summit Therapeutics as a preferred stock, which also prompted the drug developer's stock to rise 56% on Monday.

The Citigroup analyst said Summit's candidate drug "decisively beat" Keytruda and exceeded "almost all clinical expectations" of the current "gold standard" immunotherapy, indicating it is a reliable emerging blockbuster drug.

Keytruda, a pillar of Merck's revenue, not only opened a new era of tumor immunotherapy but also became the cornerstone of cancer treatment and gradually developed into one of the world's best-selling drugs. Keytruda's global sales in the first half of 2024 reached US$14.2 billion, and it is expected to exceed US$30 billion in the whole year, accounting for 45% of Merck's total revenue. Keytruda's success is attributed to its expanding indications, which have been approved for about 40 indications.

Therefore, Citigroup raised its target price to US$19 from US$13 and said that Summit is expected to continue to rise due to positive data and investors' pursuit of the company. The investment bank currently expects the peak risk-adjusted sales in the United States and Europe to be about US$7.8 billion, higher than its previous estimate of US$5.3 billion.

Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App